// App-Quantinova.ai

1643 : Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use

Researchers

Presenter

  • Oliver Distler

Principal Investigators

  • Daniel Furst

  • Eric Hachulla

  • Sindhu Johnson

  • Shervin Assassi

  • Leslie Meng

  • Manuel Quaresma

  • Margarida Alves

  • Emmanuelle Clerisme-Beaty

  • Wim Wuyts

Medical Centers

  • Experimental Rheumatology, Radboud university medical center, Nijmegen, The Netherlands, Nijmegen, Netherlands

  • Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland

  • University of Southern California, Los Angeles, CA

  • Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France,

  • Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada

  • Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX

  • Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany

  • Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium,

Locations

  • Netherlands

  • Switzerland

  • United States

  • France

  • Canada

  • Germany

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Autoimmune (AI)

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved